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Abstract
In addition to the monographs which have been pub-
lished recently by the working group ‘‘Drug Monitoring’’
of the Swiss Society of Clinical Chemistry (SSCC) w1–3x,
new monographs have been written. The aim of these
monographs is to provide an overview on the information
which is important for the request and interpretation of
the results. Therefore, the targeted readers are laboratory
health professionals and the receivers of the reports. In
this series, several antidepressant and antipsychotic
drugs are presented. It is worth noting that the mono-
graph on the antipsychotic clozapine has already been
published in 2005 w1x. Information on the indications for
therapeutic drug monitoring (TDM), protein binding,
metabolic pathways and enzymes involved, elimination
half-life time and elimination route(s) of the parent drug
and therapeutic or toxic concentrations is provided.
Because pre-analytical considerations are of particular
importance for therapeutic drug monitoring, information
regarding the optimal point in time for the determination
of drug concentrations and achievement of steady-state
concentrations after changing the dose is given. Fur-
thermore, the stability of the drug and its metabolite(s)
after blood sampling is described. For readers with a
specific interest, references to important publications are
provided. The number of the monographs will be contin-
uously increased. The updated files are presented on the
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homepage of the SSCC (www.sscc.ch). We hope that
these monographs are helpful for the better handling of
therapeutic drug monitoring and we are looking forward
to comments by the readers.
Keywords: antidepressants; antipsychotics.
Zusammenfassung
In Erga¨nzung zu den in den letzten vier Jahren publizier-
ten Arzneimittelmonographien der Arbeitsgruppe Medi-
kamente der Schweizerischen Gesellschaft fu¨r Klinische
Chemie (SGKC) w1–3x, sind nun weitere Monographien
erstellt worden. Ziel dieser Monographien ist es, dem
Labormediziner bzw. dem Empfa¨nger der Befunde eine
U¨bersicht u¨ber die wichtigsten Informationen zu geben,
die fu¨r die Veranlassung einer Analyse bzw. fu¨r die Inter-
pretation der Resultate hilfreich sind. In dieser Serie
werden eine große Zahl von Antidepressiva und Anti-
psychotika pra¨sentiert. Es muss noch darauf hingewie-
sen werden, dass die Monographie zu Clozapin,
Neuroleptikum, bereits 2005 publiziert worden ist w1x. In
den einzelnen Monographien werden klinisch pharma-
kologische Angaben wie zum Beispiel Indikation fu¨r das
Therapeutic Drug Monitoring, Proteinbindungen, Meta-
bolisierungswege und daran beteiligte Enzyme, Halb-
wertzeiten und Eliminationswege der Muttersub-
stanz, sowie Informationen zu therapeutischen bzw.
toxischen Bereichen, zur Verfu¨gung gestellt. Da die Pra¨-
analytik gerade beim Therapeutic Drug Monitoring eine
wichtige Rolle spielt, werden auch hier Angaben gemacht
zu welchem Zeitpunkt eine Bestimmung der Arzneimit-
telkonzentration sinnvoll ist und wann, nach einer Dosis-
a¨nderung, der steady-state erreicht ist. Außerdem wer-
den Angaben u¨ber die Stabilita¨t der Medikamente bzw.
ihrer Metaboliten nach der Blutentnahme gemacht. Fu¨r
die interessierten Leser sind die verwendeten Referenzen
als Zitate aufgefu¨hrt. Die Zahl der Monographien wird
fortlaufend erga¨nzt. Die aktuellsten Versionen der Mono-
graphien sind auf der Homepage der SGKC abrufbar
(www.sscc.ch). Wir hoffen, dass diese Monographien im
Umgang mit dem Therapeutic Drug Monitoring hilf-
reich sein werden und freuen uns u¨ber Kommentare und
Bemerkungen.
Schlu¨sselwo¨rter: Antidepressiva; Antipsychotika.
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Amisulpride
General
• Class of the drug Antipsychotics
• Synonym(s) –
• Common trade name(s) in Germany Solian
• Conversion factors mg/L=2.706snmol/L
nmol/L=0.370smg/L
Clinical pharmacology
• Indications for TDM Individual dose adaptation, verification of compliance, suspicion of
toxicity, side effects
• Protein binding 16%
• Elimination half-life 12 h
• Volume of distribution 6 L/kg
• Metabolism
– Main metabolic pathways Weakly metabolized (approximately 12% of the dose)
– Active metabolite(s)? None
– Inhibitor or inducer of the cytochrome No
P450 system?
– Other significant pharmacokinetic None
interactions
• Elimination of parent drug Renal (approximately 70%)
• Typical therapeutic range 100–400 mg/L (270–1080 nmol/L)
• Potentially toxic concentration Not known woverdose: 10,000 mg/L (27,060 nmol/L),
fatality: 42,000 mg/L (113,652 nmol/L)x
Pre-analytics
• Time to steady-state since beginning of 2–3 days
treatment or change of posology
• Time for blood sampling Before next dose at steady-state
• Type(s) of sample Serum or plasma
• Stability 1 week at 48C
Remarks None
References • Arzneimittelkompendium Schweiz. Basel: Documed, 2007.
• Moffat AC, Osselton D, Widdop B, editors. Clarke’s analysis
of drugs and poisons in pharmaceuticals, body fluids and post-
mortem material. 3rd ed. London/Chicago, IL: Pharmaceutical
Press, 2003.
• Service of Pharmacology and Clinical Toxicology, University
Hospital of Geneva.
http://pharmacoclin.hug-ge.ch/_library/pdf/cytp450.pdf
(accession date 27 December 2007).
• Baumann PB, Hiemke C, Ulrich S, Eckermann G, Gaertner I,
Gerlach M, et al. The AGNP-TDM expert group consensus
guidelines: therapeutic drug monitoring in psychiatry.
Pharmacopsychiatry 2004;37:246–65.
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Amitriptyline
General
• Class of the drug Antidepressants
• Synonym(s) –
• Common trade name(s) in Germany Saroten





• Indications for TDM Individual dose adaptation, verification of compliance, side effects,
suspicion of toxicity
• Protein binding 90%–95% (albumin, a1-acid glycoprotein)
• Elimination half-life 17–40 h
• Volume of distribution 6–10 L/kg
• Metabolism
– Main metabolic pathways CYP2D6, CYP3A, CYP2C19
– Active metabolite(s)? Nortriptyline, 10-hydroxyamitriptyline and 10-hydroxynortriptyline
– Inhibitor or inducer of the cytochrome No
P450 system?
– Other significant pharmacokinetic None
interactions
• Elimination of parent drug Mainly hepatic
• Typical therapeutic range 0.080–0.200 mg/L (0.288–0.722 mmol/L)
(amitriptylineqnortriptyline)
• Potentially toxic concentration )0.500 mg/L ()1.80 mmol/L) (amitriptylineqnortriptyline)
Pre-analytics
• Time to steady-state since beginning of 7–10 days
treatment or change of posology
• Time for blood sampling Before next dose at steady-state or 12–16 h after last dose
• Type(s) of sample Serum or plasma
• Stability 1 week at 48C
Remarks None
References • Arzneimittelkompendium Schweiz. Basel: Documed, 2006.
• Baselt RC. Disposition of toxic drugs and chemicals in men,
7th ed. Foster City, CA: Biomedical Publications, 2004.
• Schweizerische Gesellschaft fu¨r Klinische Pharmakologie und
Toxikologie, Grundlagen der Arzneimitteltherapie (16. Auflage).
Basel: Documed, 2005.
• Evans WE, Oellerich M, Holt DW. Therapeutic drug
monitoring: clinical guide, 2nd ed. Wiesbaden:
Abbott Laboratories, Diagnostic Division, 1994.
• Baumann PB, Hiemke C, Ulrich S, Eckermann G, Gaertner I,
Gerlach M, et al. The AGNP-TDM expert group consensus
guidelines: therapeutic drug monitoring in psychiatry.
Pharmacopsychiatry 2004;37:246–65.
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Aripiprazole
General
• Class of the drug Antipsychotics
• Synonym(s) –
• Common trade name(s) in Germany Abilify





• Indications for TDM Individual dose adaptation, verification of compliance, side effects,
suspicion of toxicity
• Protein binding 99%
• Elimination half-life 75 h
• Volume of distribution 5 L/kg
• Metabolism
– Main metabolic pathways CYP3A4, CYP2D6
– Active metabolite(s)? Dehydroaripiprazole
– Inhibitor or inducer of the cytochrome No
P450 system?
– Other significant pharmacokinetic None
interactions
• Elimination of parent drug Mainly hepatic
• Typical therapeutic range Preliminary data:
Aripiprazole: 100–300 mg/L (220–670 nmol/L)
• Potentially toxic concentration Not known
Pre-analytics
• Time to steady-state since beginning of ;2 weeks
treatment or change of posology
• Time for blood sampling Before next dose at steady-state
• Type(s) of sample Serum or plasma
• Stability Several days at 48C
Remarks Almost no studies available on TDM of aripiprazole and its main
active metabolite dehydroaripiprazole.
References • Arzneimittelkompendium Schweiz. Basel: Documed, 2006.
• Kubo M, Mizooku Y, Hirao Y, Osumi T. Development and
validation of an LC-MS/MS method for the quantitative
determination of aripiprazole and its main metabolite, OPC-
14857, in human plasma. J Chromatogr B Analyt Technol
Biomed Life Sci 2005;822:294–9.
• DeLeon A, Patel NC, Crismon ML. Aripiprazole: a
comprehensive review of its pharmacology, clinical efficacy,
and tolerability. Clin Ther 2004;26:649–66.
• Mallikaarjun S, Salazar DE, Bramer SL. Pharmacokinetics,
tolerability, and safety of aripiprazole following multiple oral
dosing in normal healthy volunteers. J Clin Pharmacol
2004;44:197–87.
• Product information, BMS.
• Kirschbaum KM, Mu¨ller MJ, Zernig G, Saria A, Moascher A,
et al. Therapeutic drug monitoring of aripiprazole by HPLC
with column-switching and spectrophotometric detection.
Clin Chem 2005;51:1718–21.
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Clomipramine
General
• Class of the drug Antidepressants
• Synonym(s) –
• Common trade name(s) in Germany Anafranil
• Conversion factors mg/L=3.18smmol/L
mmol/L=0.315smg/L
Clinical pharmacology
• Indications for TDM Individual dose adaptation, verification of compliance, side
effects, suspicion of toxicity
• Protein binding 90–98% (albumin, a1-glycoprotein)
• Elimination half-life Clomipramine: 19–37 h
N-Desmethylclomipramine: 54–77 h
• Volume of distribution 12–17 L/kg
• Metabolism
– Main metabolic pathways CYP2D6, CYP3A4, CYP1A2
– Active metabolite(s)? N-Desmethylclomipramine
– Inhibitor or inductor of the cytochrome No
P450 system?
– Other significant pharmacokinetic None
interactions
• Elimination of parent drug Mainly hepatic
• Typical therapeutic range ClomipramineqN-Desmethylclomipramine: 0.175–0.450 mg/L (0.557–1.43 mmol/L)
• Potentially toxic concentration )0.450 mg/L ()1.272 mmol/L)
Pre-analytics
• Time to steady-state since beginning of 7–14 days
treatment or change of posology
• Time for blood sampling Before next dose at steady-state or 12–16 h after last dose
• Type(s) of sample Serum or plasma
• Stability 1 week at 48C
Remarks None
References • Arzneimittelkompendium Schweiz. Basel: Documed, 2005.
• Baselt RC. Disposition of toxic drugs and chemicals in men,
7th ed. Foster City, CA: Biomedical Publications, 2004.
• Schweizerische Gesellschaft fu¨r Klinische Pharmakologie und
Toxikologie, Grundlagen der Arzneimitteltherapie (16. Auflage).
Basel: Documed, 2005.
• Evans WE, Oellerich M, Holt DW. Therapeutic drug
monitoring: clinical guide, 2nd ed.
Abbott Laboratories, Diagnostic Division, 1994.
• Baumann PB, Hiemke C, Ulrich S, Eckermann G, Gaertner I,
Gerlach M, et al. The AGNP-TDM expert group consensus
guidelines: therapeutic drug monitoring in psychiatry.
Pharmacopsychiatry 2004;37:246–65.
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Duloxetine
General
• Class of the drug Antidepressants
• Synonym(s) –
• Common trade name(s) in Germany Yentreve
• Conversion factors mg/L=3.37snmol/L
nmol/L=0.297smg/L
Clinical pharmacology
• Indications for TDM Individual dose adaptation, verification of compliance, side
effects, suspicion of toxicity
• Protein binding )90%
• Elimination half-life 8–17 h
• Volume of distribution 23 L/kg
• Metabolism
– Main metabolic pathways CYP1A2 and CYP2D6
– Active metabolite(s)? None
– Inhibitor or inductor of the cytochrome Not known
P450 system?
– Other significant pharmacokinetic Not known
interactions
• Elimination of parent drug Hepatic
• Typical therapeutic range 15–150 mg/L (50–500 nmol/L)
• Potentially toxic concentration Not known
Pre-analytics
• Time to steady-state since beginning of ;3 days
treatment or change of posology
• Time for blood sampling Before next dose at steady-state
• Type(s) of sample Serum or plasma
• Stability 1 week at 48C
Remarks None
References • Arzneimittelkompendium Schweiz. Basel: Documed, 2007.
• Anderson D, Reed S, Lintemoot J, Kegler S, De Quintana S,
Sandberg M, et al. A first look at duloxetine (Cymbalta) in a
postmortem laboratory. J Anal Toxicol 2006;30:576–80.
• Satonin DK, McCulloch JD, Kuo F, Knadler MP.
Development and validation of a liquid chromatography-tandem
mass spectrometric method for the determination of the
major metabolites of duloxetine in human plasma. J Chromatogr
B Analyt Technol Biomed Life Sci 2007;852:582–9.
• Mercolini L, Mandrioli R, Cazzolla R, Amore M, Raggi MA.
HPLC analysis of the novel antidepressant duloxetine in
human plasma after an original solid phase extraction
procedure. J Chromatogr B Analyt Technol Biomed Life Sci
2007;856:81–7.
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Fluvoxamine
General
• Class of the drug Antidepressants
• Synonym(s) –
• Common trade name(s) in Germany Fevarin
• Conversion factors mg/L=3.141snmol/L
nmol/L=0.318smg/L
Clinical pharmacology
• Indications for TDM Individual dose adaptation, verification of compliance, suspicion
of toxicity, side effects
• Protein binding 80% (mainly to albumin)
• Elimination half-life 17–22 h
• Volume of distribution 25 L/kg
• Metabolism
– Main metabolic pathways CYP2D6 (major)
– Active metabolite(s)? None
– Inhibitor or inducer of the cytochrome Strong inhibition: CYP1A2, CYP2C19
P450 system? Moderate inhibition: CYP2C9, CYP2D6, CYP3A4/5
– Other significant pharmacokinetic None
interactions
• Elimination of parent drug Hepatic
• Typical therapeutic range 150–300 mg/L (470–940 nmol/L)
• Potentially toxic concentration Not known
Pre-analytics
• Time to steady-state since beginning of 4 days
treatment or change of posology
• Time for blood sampling Before next dose at steady-state
• Type(s) of sample Serum or plasma
• Stability 1 week at 48C
Remarks None
References • Arzneimittelkompendium Schweiz. Basel: Documed, 2007.
• Moffat AC, Osselton D, Widdop B, editors. Clarke’s analysis of drugs
and poisons in pharmaceuticals, body fluids and post-mortem material,
3rd ed. London/Chicago, IL: Pharmaceutical Press, 2003.
• Service of Pharmacology and Clinical Toxicology, University Hospital
of Geneva. http://pharmacoclin.hug-ge.ch/_library/pdf/cytp450.pdf
(accession date 27 December 2007).
• Baumann PB, Hiemke C, Ulrich S, Eckermann G, Gaertner I, Gerlach
M, et al. The AGNP-TDM expert group consensus guidelines:
therapeutic drug monitoring in psychiatry. Pharmacopsychiatry
2004;37:246–65.
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Haloperidol
General
• Class of the drug Neuroleptics
• Synonym(s) –
• Common trade name(s) in Germany Haldol, Haldol decanoat
• Conversion factors mg/L=2.66snmol/L
nmol/L=0.38smg/L
Clinical pharmacology
• Indications for TDM Individual dose adaptation, verification of compliance, side effects,
suspicion of toxicity
• Protein binding 92%
• Elimination half-life 24 h (12–38 h)
• Volume of distribution 7.9"2.5 L/kg
• Metabolism
– Main metabolic pathways CYP3A4, CYP2D6 and reduction
– Active metabolite(s)? None
– Inhibitor or inducer of the cytochrome Reduced haloperidol (metabolite; inhibits CYP2D6)
P450 system?
– Other significant pharmacokinetic No
interactions
• Elimination of parent drug Mainly hepatic
• Typical therapeutic range 5.0–17.0 mg/L (13.0–45.2 nmol/L)
• Potentially toxic concentration 49.4 mg/L ()130 nmol/L)
Pre-analytics
• Time to steady-state since beginning of ;5 days
treatment or change of posology
• Time for blood sampling Before next dose at steady state
• Type(s) of sample Serum or plasma
• Stability One week at 48C
Remarks None
References • Arzneimittelkompendium Schweiz. Basel: Documed, 2005.
• Llerena A, Alm C, Dahl ML, Ekqvist B, Bertilsson L. Haloperidol
disposition is dependent on debrisoquine hydroxylation phenotype.
Ther Drug Monit 1992;14:92–7.
• Pan L, Rosseel MT, Belpaire FM. Comparison of two high-
performance liquid chromatographic methods for monitoring plasma
concentrations of haloperidol and reduced haloperidol. Ther Drug
Monit 1998;20:224–30.
• Angelo HR, Petersen A. Therapeutic drug monitoring of haloperidol,
perphenazine, and zuclopenthixol in serum by a fully automated
sequential solid phase extraction followed by high-performance liquid
chromatography. Ther Drug Monit 2001;23:157–62.
• Baumann PB, Hiemke C, Ulrich S, Eckermann G, Gaertner I, Gerlach
M, et al. The AGNP-TDM expert group consensus guidelines:
therapeutic drug monitoring in psychiatry. Pharmacopsychiatry
2004;37:246–65.
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Imipramine
General
• Class of the drug Antidepressants
• Synonym(s) –
• Common trade name(s) in Germany Tofranil
• Conversion factors mg/L=3.57smmol/L
mmol/L=0.280smg/L
Clinical pharmacology
• Indications for TDM Individual dose adaptation, verification of compliance, side effects,
suspicion of toxicity
• Protein binding 63–96%
• Elimination half-life 6–28 h (11–37 h)
• Volume of distribution 16–20 L/kg
• Metabolism
– Main metabolic pathways CYP2D6, CYP3A4, CYP2C19, CYP1A2
– Active metabolite(s)? 2-OH-imipramine, desipramine, 2-OH-desipramine
– Inhibitor or inducer of the cytochrome No
P450 system?
– Other significant pharmacokinetic None
interactions
• Elimination Mainly hepatic
• Typical therapeutic range ImipramineqDesipramine: 0.15–0.25 mg/L (0.54–0.89 mmol/L)
• Potentially toxic concentration )1.0 mg/L ()3.57 mmol/L)
Pre-analytics
• Time to steady-state since beginning of 2–5 days
treatment or change of posology
• Time for blood sampling Before next dose at steady-state
• Type(s) of sample Serum or plasma
• Stability 1 week at 48C
Remarks None
References • Arzneimittelkompendium Schweiz. Basel: Documed, 2005.
• Baselt RC. Disposition of toxic drugs and chemicals in men, 7th ed.
Foster City, CA: Biomedical Publications, 2004.
• Schweizerische Gesellschaft fu¨r Klinische Pharmakologie und
Toxikologie, Grundlagen der Arzneimitteltherapie (16. Auflage).
Basel: Documed, 2005.
• Evans WE, Oellerich M, Holt DW. Therapeutic drug monitoring:
clinical guide, 2nd ed. Abbott Laboratories,
Diagnostic Division, 1994.
• Baumann PB, Hiemke C, Ulrich S, Eckermann G, Gaertner I, Gerlach
M, et al. The AGNP-TDM expert group consensus guidelines:
therapeutic drug monitoring in psychiatry. Pharmacopsychiatry
2004;37:246–65.
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Levomepromazine
General
• Class of the drug Antipsychotics
• Synonym(s) Methotrimeprazine
• Common trade name(s) in Germany Neurocil
• Conversion factors mg/L=3.05snmol/L
nmol/L=0.328smg/L
Clinical pharmacology
• Indications for TDM Individual dose adaptation, verification of compliance, side effects,
suspicion of toxicity
• Protein binding 99%
• Elimination half-life 15–30 h
• Volume of distribution 30 L/kg
• Metabolism
– Main metabolic pathways CYP2D6
– Active metabolite(s)? None
– Inhibitor or inductor of the cytochrome Inhibition of CYP2D6
P450 system?
– Other significant pharmacokinetic None
interactions
• Elimination of parent drug Mainly hepatic
• Typical therapeutic range 15–60 mg/L (46–183 nmol/L)
• Potentially toxic concentration )3660 mg/L ()1200 nmol/L)
Pre-analytics
• Time to steady-state since beginning of ;5 days
treatment or change of posology
• Time for blood sampling Before next dose at steady-state
• Type(s) of sample Serum or plasma
• Stability 1 week at 48C
Remarks None
References • Arzneimittelkompendium Schweiz. Basel: Documed, 2007.
• Brown G, Scott W, Walker S. Sedation in the intensive care unit. Can J
Hosp Pharm 1996;49:279–80.
• Stahl S. Selecting an atypical antipsychotic by combined clinical
experience with guidelines from clinical trials. J Clin Psychiatry
1990;60:31–41.
• Canales PL, Olsen J, Miller AL, Crismon ML. Role of antipsychotic
polypharmacotherapy in the treatment of schizophrenia. CNS Drugs
1999;12:179–88.
• Loennechen T, Dahl SG. High-performance liquid chromatography of
levomepromazine (methotrimeprazine) and its main metabolites. J
Chromatogr 1990;503:205–15.
• Josefsson M, Kronstrand R, Andersson J, Roman M. Evaluation of
electrospray ionization liquid chromatography-tandem mass
spectrometry for rational determination of a number of neuroleptics
and their major metabolites in human body fluids and tissues. J
Chromatogr B Analyt Technol Biomed Life Sci 2003;789:151–67.
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Lithium
General
• Class of the drug Antidepressant
• Synonym(s) –
• Common trade name(s) in Germany Quilonorm: lithium carbonate
Togal CLASSIC: lithium citrate
• Conversion factors mmol/L=6.94smg/L
mg/L=0.144smmol/L
Clinical pharmacology
• Indications for TDM Mandatory for individual dose adaptation, verification of compliance,
side effects, suspicion of toxicity
• Protein binding 0%
• Elimination half-life 15–30 h
• Volume of distribution 0.7–0.9 L/kg
• Metabolism
– Main metabolic pathways No metabolism
– Active metabolite(s)? None
– Inhibitor or inducer of the cytochrome No
P450 system?
– Other significant pharmacokinetic Numerous interactions with anti-inflammatory non-steroidal drugs, ACE
interactions inhibitors, various diuretics, «
• Elimination of parent drug Renal )95%
• Typical therapeutic range 0.5–1.2 mmol/L
• Potentially toxic concentration )1.5 mmol/L
Pre-analytics
• Time to steady-state since beginning of 5–7 days
treatment or change of posology
• Time for blood sampling Before next dose at steady-state
• Type(s) of sample Serum
• Stability 4 days at 48C
For longer conservation, freeze at –208C
Remarks None
References • Arzneimittelkompendium Schweiz. Basel: Documed, 2005.
• Schweizerische Gesellschaft fu¨r Klinische Pharmakologie und
Toxikologie, Grundlagen der Arzneimitteltherapie (15. Auflage). Basel:
Documed, 2001.
• Magnin J-L. Lithium: me´dicament et outil diagnostic. Labolife 1997; 2:21.
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Maprotiline
General
• Class of the drug Antidepressants
• Synonym(s) –
• Common trade name(s) in Germany Ludiomil
• Conversion factors mg/L=3.61snmol/L
nmol/L=0.277smg/L
Clinical pharmacology
• Indications for TDM Individual dose adaptation, verification of compliance, side effects,
suspicion of toxicity
• Protein binding 90%
• Elimination half-life 43–45 h
• Volume of distribution 23–27 L/kg
• Metabolism
– Main metabolic pathways CYP2D6
– Active metabolite(s)? Desmethylmaprotiline
– Inhibitor or inducer of the cytochrome Not known
P450 system?
– Other significant pharmacokinetic None
interactions
• Elimination of parent drug Mainly hepatic
• Typical therapeutic range 125–200 mg/L (451–720 nmol/L)
• Potentially toxic concentration )554 mg/L ()2000 nmol/L)
Pre-analytics
• Time to steady-state since beginning of ;8 days
treatment or change of posology
• Time for blood sampling Before next dose at steady-state
• Type(s) of sample Serum or plasma
• Stability 1 week at 48C
Remarks None
References • Arzneimittelkompendium Schweiz. Basel: Documed, 2007.
• Kuss HJ, Sirch S, Zhao DY. Assay for maprotiline in human serum with
improved sensitivity and selectivity. J Chromatogr B Biomed Appl
1994;656:245–9.
• Ko¨nig F, Wolfersdorf M, Lo¨ble M, Hauger B. Trimipramine and
maprotiline plasma levels during combined treatment with moclobemide
in therapy-resistant depression. Pharmacopsychiatry 1997;30:154–7.
• Aymard G, Livi P, Pham YT, Diquet B. Sensitive and rapid method for
the simultaneous quantification of five antidepressants with their
respective metabolites in plasma using high-performance liquid
chromatography with diode-array detection. J Chromatogr B Biomed Sci
Appl 1997;700:183–9.
• Firkusny L, Gleiter CH. Maprotiline metabolism appears to co-segregate
with the genetically-determined CYP2D6 polymorphic hydroxylation of
debrisoquine. Br J Clin Pharmacol 1994;37:383–8.
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Mianserin
General
• Class of the drug Antidepressants
• Synonym(s) –
• Common trade name(s) in Germany Tolvin





• Indications for TDM Individual dose adaptation, verification of compliance, side effects,
suspicion of toxicity
• Protein binding 90%
• Elimination half-life Mianserin: 15–22 h
Desmethylmianserin: 5–21 h
• Volume of distribution 13 L/kg
• Metabolism
– Main metabolic pathways CYP1A2, CYP2D6
– Active metabolite(s)? Desmethylmianserin
– Inhibitor or inducer of the cytochrome No
P450 system?
– Other significant pharmacokinetic None
interactions
• Elimination of parent drug Mainly hepatic
• Typical therapeutic range Mianserin: 15–70 mg/L (57–265 nmol/L)
• Potentially toxic concentration )500 mg/L ()1900 nmol/L)
Pre-analytics
• Time to steady-state since beginning of ;5 days
treatment or change of posology
• Time for blood sampling Before next dose at steady-state
• Type(s) of sample Serum or plasma
• Stability 1 week at 48C
Remarks Chiral drug: enantiomers differ by their metabolism and pharmacology
References • Arzneimittelkompendium Schweiz. Basel: Documed, 2005.
• Baumann PB, Hiemke C, Ulrich S, Eckermann G, Gaertner I, Gerlach
M, et al. The AGNP-TDM expert group consensus guidelines:
therapeutic drug monitoring in psychiatry. Pharmacopsychiatry
2004;37:246–65.
• Eap CB, Yasui N, Kaneko S, Baumann P, Powell K. Otani K. Effects
of carbamazepine coadministration on plasma concentrations of the
enantiomers of mianserin and of its metabolites. Ther Drug Monit
1999;21:166–70.
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Mirtazapine
General
• Class of the drug Antidepressants
• Synonym(s) –
• Common trade name(s) in Germany Remergil





• Indications for TDM Individual dose adaptation, verification of compliance, side effects,
suspicion of toxicity
• Protein binding 85%
• Elimination half-life 20–40 h
• Volume of distribution 4.5 L/kg
• Metabolism
– Main metabolic pathways CYP3A4, CY2PD6
– Active metabolite(s)? Desmethylmirtazapine
– Inhibitor or inducer of the cytochrome No
P450 system?
– Other significant pharmacokinetic No
interactions
• Elimination of parent drug Hepatic 80%
Renal -20%
• Typical therapeutic range Mirtazapine: 40–80 mg/L (150–300 nmol/L)
Desmethylmirtazapine: 5.0–20.0 mg/L (20–80 nmol/L)
• Potentially toxic concentration Not known
Pre-analytics
• Time to steady-state since beginning of ;5 days
treatment or change of posology
• Time for blood sampling Before next dose at steady-state
• Type(s) of sample Serum or plasma
• Stability 1 week at 48C
Remarks • Chiral drug
• Enantiomers differ by their metabolism and pharmacology
References • Arzneimittelkompendium Schweiz. Basel: Documed, 2005.
• Delbressine LP, Moonen ME, Kaspersen FM, Wagenaars GN, Jacobs
PL, Timmer CJ, et al. Pharmacokinetics and biotransformation of
mirtazapine in human volunteers. Clin Drug Invest 1998;15:45–55.
• Pistos C, Koutsopoulou M, Panderi I. A validated liquid
chromatographic tandem mass spectrometric method for the
determination of mirtazapine and desmethylmirtazapine in human
plasma: application to a pharmacokinetic study. Anal Chim
Acta 2004:514:15–26.
• Shams M, Hiemke C, Ha¨rtter S. Therapeutic drug monitoring of the
antidepressant mirtazapine and its N-demethylated metabolite in
human serum. Ther Drug Monit 2004;26:78–84.
• Baumann PB, Hiemke C, Ulrich S, Eckermann G, Gaertner I, Gerlach
M, et al. The AGNP-TDM expert group consensus guidelines:
therapeutic drug monitoring in psychiatry. Pharmacopsychiatry
2004;37:246–65.
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Nortriptyline
General
• Class of the drug Antidepressants
• Synonym(s) –
• Common trade name(s) in Germany Nortrilen
• Conversion factors mg/L=3.80 smmol/L
mmol/L=0.263smg/L
Clinical pharmacology
• Indications for TDM Individual dose adaptation, verification of compliance, side effects,
suspicion of toxicity
• Protein binding 87–93%
• Elimination half-life 18–56 h
• Volume of distribution 20–57 L/kg
• Metabolism
– Main metabolic pathways CYP2D6
– Active metabolite(s)? 10-hydroxynortriptyline
– Inhibitor or inducer of the cytochrome No
P450 system?
– Other significant pharmacokinetic None
interactions
• Elimination of parent drug Mainly hepatic
• Typical therapeutic range 0.070–0.170 mg/L (0.266–0.646 mmol/L)
• Potentially toxic concentration )0.500 mg/L ()1.805 mmol/L)
Pre-analytics
• Time to steady-state since beginning of 4–20 days
treatment or change of posology
• Time for blood sampling Before next dose at steady-state
• Type(s) of sample Serum or plasma
• Stability 1 week at 48C
Remarks None
References • Arzneimittelkompendium Schweiz. Basel: Documed, 2005.
• Baselt RC. Disposition of toxic drugs and chemicals in men, 7th ed.
Foster City, CA: Biomedical Publications, 2004.
• Schweizerische Gesellschaft fu¨r Klinische Pharmakologie und
Toxikologie, Grundlagen der Arzneimitteltherapie (16. Auflage). Basel:
Documed, 2005.
• Evans WE, Oellerich M, Holt DW. Therapeutic drug monitoring:
clinical guide, 2nd ed. Abbott Laboratories,
Diagnostic Division, 1994.
• Baumann PB, Hiemke C, Ulrich S, Eckermann G, Gaertner I, Gerlach
M, et al. The AGNP-TDM expert group consensus guidelines:
therapeutic drug monitoring in psychiatry. Pharmacopsychiatry
2004;37:246–65.
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Paroxetine
General
• Class of the drug Antidepressants
• Synonym(s) –
• Common trade name(s) in Germany Seroxat, Tagonis
• Conversion factors mg/L=3.03snmol/L
nmol/L=0.33smg/L
Clinical pharmacology
• Indications for TDM Individual dose adaptation, verification of compliance, side effects,
suspicion of toxicity
• Protein binding 95%
• Elimination half-life 24 h (6–71 h)
• Volume of distribution 17 L/kg
• Metabolism
– Main metabolic pathways CYP2D6
– Active metabolite(s)? None
– Inhibitor or inducer of the cytochrome Inhibitor of CYP2D6
P450 system?
– Other significant pharmacokinetic Not known
interactions
• Elimination of parent drug Hepatic 36%
Renal 64%
• Typical therapeutic range 70–120 mg/L (200–365 nmol/L)
• Potentially toxic concentration Not known
Pre-analytics
• Time to steady-state since beginning of ;5 days
treatment or change of posology
• Time for blood sampling Before next dose at steady-state
• Type(s) of sample Serum or plasma
• Stability 1 week at 48C
Remarks None
References • Arzneimittelkompendium Schweiz. Basel: Documed, 2006.
• Foglia JP, Sorisio D, Kirshner M, Pollock BG. Quantitative
determination of paroxetine in plasma by high-performance liquid
chromatography and ultraviolet detection. J Chromatogr B Biomed
Sci Appl 1997;693:147–51.
• Linder MW, Keck PE Jr. Standards of laboratory practice:
antidepressant drug monitoring. National Academy of Clinical
Biochemistry. Clin Chem 1998;44:1073–84.
• Lucca A, Gentilini G, Lopez-Silva S, Soldarini A. Simultaneous
determination of human plasma levels of four selective serotonin
reuptake inhibitors by high-performance liquid chromatography. Ther
Drug Monit 2000;22:271–6.
• Montgomery SA. Efficacy in long-term treatment of depression. J Clin
Psychiatry 1996;57(Suppl 2):24–30.
• Baumann PB, Hiemke C, Ulrich S, Eckermann G, Gaertner I, Gerlach M, et al.
The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring
in psychiatry. Pharmacopsychiatry 2004;37:246–65.
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Quetiapine
General
• Class of the drug Antipsychotics
• Synonym(s) –
• Common trade name(s) in Germany Seroquel
• Conversion factors mg/L=2.607s nmol/L
nmol/L=0.38smg/L
Clinical pharmacology
• Indications for TDM Individual dose adaptation, verification of compliance, side effects,
suspicion of toxicity
• Protein binding 83%
• Elimination half-life 5–7 h
• Volume of distribution 7–10 L/kg
• Metabolism
– Main metabolic pathways CYP3A4 (quetiapine sulfoxide formation)
– Active metabolite(s)? Clinically not relevant
– Inhibitor or inducer of the cytochrome No
P450 system?
– Other significant pharmacokinetic None
interactions
• Elimination of parent drug Mainly hepatic
• Typical therapeutic range 70–170 mg/L (182–443 nmol/L)
• Potentially toxic concentration Not known wfatality: 18,000 mg/L (47,000 nmol/L)x
Pre-analytics
• Time to steady-state since beginning of 2–3 days
treatment or change of posology
• Time for blood sampling Before next dose at steady-state
• Type(s) of sample Serum or plasma
• Stability 1 week at 48C
Remarks Quetiapine plasma concentrations show a wide interindividual variation
References • Arzneimittelkompendium Schweiz. Basel: Documed, 2006.
• De Vane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an
atypical antipsychotic. Clin Pharmacokinet 2001;40:509–22.
• Hasselstrom J, Linnet K. Quetiapine serum concentrations in psychiatric
patients: the influence of comedication. Ther Drug Monit 2004;26:486–91.
• Fernandes PP, Marcil WA. Death associated with quetiapine overdose.
Am J Psychiatr 2002;159:2114.
• Baumann PB, Hiemke C, Ulrich S, Eckermann G, Gaertner I, Gerlach M,
et al. The AGNP-TDM expert group consensus guidelines: therapeutic
drug monitoring in psychiatry. Pharmacopsychiatry 2004;37:246–65.
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Risperidone
General
• Class of the drug Antipsychotics
• Synonym(s) –
• Common trade name(s) in Germany Risperdal, Risperdal Consta





• Indications for TDM Individual dose adaptation, verification of compliance, side effects,
suspicion of toxicity
• Protein binding 90% (risperidone), 77% (9-OH-risperidone)
• Elimination half-life Risperidone: 3–4 h
9-OH-risperidone: 15–25 h
• Volume of distribution 1 L/kg
• Metabolism
– Main metabolic pathways CYP2D6
– Active metabolite(s)? 9-OH-risperidone
– Inhibitor or inducer of the cytochrome No
P450 system?
– Other significant pharmacokinetic CYP2D6 inhibitors increase risperidone, with a non-fully compensating
interactions decrease of 9-OH-risperidone
• Elimination of parent drug Mainly hepatic (active metabolite mainly renal)
• Typical therapeutic range Risperidoneq9-OH-risperidone (s‘‘active moiety’’):
20–60 mg/L (49–146 nmol/L)
• Potentially toxic concentration Not known
Pre-analytics
• Time to steady-state since beginning of ;3–5 days
treatment or change of posology
• Time for blood sampling Before next dose at steady-state
• Type(s) of sample Serum or plasma
• Stability 1 week at 48C
Remarks With long acting (depot) risperidone, steady-state conditions are only
reached after 4 injections every 2 weeks (8 weeks after 1st injection).
Apparent half-life of ‘‘active moiety’’, after administration of long acting
risperidone: 3–6 days
The active metabolite 9-OH-risperidon undergoes renal elimination
References • Arzneimittelkompendium Schweiz. Basel: Documed, 2006.
• Grant S, Fitton A. Risperidone. A review of its pharmacology and
therapeutic potential in the treatment of schizophrenia. Drugs
1994;48:253–73.
• Marder SR, Conley R, Ereshefsky L, Kane JM, Turner MS. Clinical
guidelines: dosing and switching strategies for long-acting risperidone. J
Clin Psychiatry 2003;64:41–6.
• Harrison TS, Goa KL. Long-acting risperidone: a review of its use in
schizophrenia. CNS Drugs 2004;18:113–32.
• Baumann PB, Hiemke C, Ulrich S, Eckermann G, Gaertner I, Gerlach M,
et al. The AGNP-TDM expert group consensus guidelines: therapeutic
drug monitoring in psychiatry. Pharmacopsychiatry 2004;37:246–65.
• Wilson WH. A visual guide to expected blood levels of long-acting
injectable risperidone in clinical practice. J Psychiatr Pract
2004;10:393–401.
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Sertraline
General
• Class of the drug Antidepressants
• Synonym(s) –
• Common trade name(s) in Germany Gladem, Zoloft
• Conversion factors mg/L=3.26snmol/L
nmol/L=0.31smg/L
Clinical pharmacology
• Indications for TDM Individual dose adaptation, verification of compliance, side effects,
suspicion of toxicity
• Protein binding 98%
• Elimination half-life 22–36 h for sertraline
62–104 h for N-Desmethylsertraline
• Volume of distribution )20 L/kg
• Metabolism
– Main metabolic pathways CYP2B6
– Active metabolite(s)? N-Desmethylsertraline
– Inhibitor or inducer of the cytochrome Weak inhibitor of CYP2D6 and CYP3A4
P450 system?
– Other significant pharmacokinetic No
interactions
• Elimination of parent drug Hepatic 50%
Renal 50%
• Typical therapeutic range 10–50 mg/L (33–163 nmol/L)
• Potentially toxic concentration Not known
Pre-analytics
• Time to steady-state since beginning of ;5 days
treatment or change of posology
• Time for blood sampling Before next dose at steady-state
• Type(s) of sample Serum or plasma
• Stability 1 week at 48C
Remarks None
References • Arzneimittelkompendium Schweiz. Basel: Documed, 2005.
• Linder MW, Keck PE Jr. Standards of laboratory practice:
antidepressant drug monitoring. National Academy of Clinical
Biochemistry. Clin Chem 1998;44:1073–84.
• Lucca A, Gentilini G, Lopez-Silva S, Soldarini A. Simultaneous
determination of human plasma levels of four selective serotonin
reuptake inhibitors by high-performance liquid chromatography. Ther
Drug Monit 2000;22:271–6.
• Montgomery SA. Efficacy in long-term treatment of depression. J Clin
Psychiatry 1996;57(Suppl 2):24–30.
• Baumann PB, Hiemke C, Ulrich S, Eckermann G, Gaertner I, Gerlach M,
et al. The AGNP-TDM expert group consensus guidelines: therapeutic
drug monitoring in psychiatry. Pharmacopsychiatry 2004;37:246–65.
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Trazodone
General
• Class of the drug Antidepressants
• Synonym(s) –
• Common trade name(s) in Germany Thombran
• Conversion factors mg/L=0.027smmol/L
mmol/L=372smg/L
Clinical pharmacology
• Indications for TDM Individual dose adaptation, verification of compliance, suspicion of
toxicity, side effects
• Protein binding 90%
• Elimination half-life 4–7 h
• Volume of distribution Unknown
• Metabolism
– Main metabolic pathways CYP3A4
– Active metabolite(s)? m-chlorophenyl-piperazine or mCPP (minor)
– Inhibitor or inducer of the cytochrome No
P450 system?
– Other significant pharmacokinetic Reported cases of increased levels of digoxin and phenytoin
interactions
• Elimination of parent drug Hepatic
• Typical therapeutic range 650–1500 mg/L (1.75–4.03 mmol/L)
• Potentially toxic concentration Not known wfatalities: 9000–33,000 mg/L (243–891 mmol/L)x
Pre-analytics
• Time to steady-state since beginning of 2–3 days
treatment or change of posology
• Time for blood sampling Before next dose at steady-state
• Type(s) of sample Serum or plasma
• Stability 1 week at 48C
Remarks None
References • Arzneimittelkompendium Schweiz. Basel: Documed, 2007.
• Moffat AC, Osselton D, Widdop B, editors. Clarke’s analysis of drugs
and poisons in pharmaceuticals, body fluids and post-mortem material,
3rd ed. London/Chicago, IL: Pharmaceutical Press, 2003.
• Service of Pharmacology and Clinical Toxicology, University Hospital
of Geneva. http://pharmacoclin.hug-ge.ch/_library/pdf/cytp450.pdf
(accession date 27 December 2007).
• Baumann PB, Hiemke C, Ulrich S, Eckermann G, Gaertner I, Gerlach M,
et al. The AGNP-TDM expert group consensus guidelines: therapeutic
drug monitoring in psychiatry. Pharmacopsychiatry 2004;37:246–65.
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Trimipramine
General
• Class of the drug Antidepressants
• Synonym(s) –
• Common trade name(s) in Germany Stangyl
• Conversion factors mg/L=0.00397smmol/L
mmol/L=294smg/L
Clinical pharmacology
• Indications for TDM Individual dose adaptation, verification of compliance, suspicion of
toxicity, side effects
• Protein binding 94%
• Elimination half-life 16–40 h (mean 24 h)
• Volume of distribution 20–50 L/kg
• Metabolism
– Main metabolic pathways CYP2D6
– Active metabolite(s)? N-desmethyltrimipramine
– Inhibitor or inducer of the cytochrome No
P450 system?
– Other significant pharmacokinetic None
interactions
• Elimination of parent drug Hepatic
• Typical therapeutic range 150–350 mg/L (0.51–1.19 mmol/L)
• Potentially toxic concentration )1000 mg/L ()3.4 mmol/L) wfatalities: 9000–12,000 mg/L
(30.6–47.6 mmol/L)x
Pre-analytics
• Time to steady-state since beginning of 4–7 days
treatment or change of posology
• Time for blood sampling Before next dose at steady-state
• Type(s) of sample Serum or plasma
• Stability 1 week at 48C
Remarks None
References • Arzneimittelkompendium Schweiz. Basel: Documed, 2007.
• Moffat AC, Osselton D, Widdop B, editors. Clarke’s analysis of drugs
and poisons in pharmaceuticals, body fluids and post-mortem material,
3rd ed. London/Chicago, IL: Pharmaceutical Press, 2003.
• Service of Pharmacology and Clinical Toxicology, University Hospital
of Geneva. http://pharmacoclin.hug-ge.ch/_library/pdf/cytp450.pdf
(accession date 27 December 2007).
• Baumann PB, Hiemke C, Ulrich S, Eckermann G, Gaertner I, Gerlach
M, et al. The AGNP-TDM expert group consensus guidelines:
therapeutic drug monitoring in psychiatry. Pharmacopsychiatry
2004;37:246–65
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Venlafaxine
General
• Class of the drug Antidepressants
• Synonym(s) –
• Common trade name(s) in Germany Trevilor





• Indications for TDM Individual dose adaptation, verification of compliance, side effects,
suspicion of toxicity
• Protein binding 30% (venlafaxine)
• Elimination half-life 4 h (venlafaxine), 10 h (O-desmethylvenlafaxine)
• Volume of distribution 7 L/kg
• Metabolism
– Main metabolic pathways CYP2D6
– Active metabolite(s)? Mainly O-desmethylvenlafaxine
– Inhibitor or inducer of the cytochrome No
P450 system?
– Other significant pharmacokinetic None
interactions
• Elimination of parent drug Mainly hepatic
• Typical therapeutic range VenlafaxineqO-desmethylvenlafaxine: 195–400 mg/L (721–1480 nmol/L)
• Potentially toxic concentration Not known
Pre-analytics
• Time to steady-state since beginning of 2–3 days
treatment or change of posology
• Time for blood sampling Before next dose at steady-state
• Type(s) of sample Serum or plasma
• Stability: 1 week at 48C
Remarks Chiral drug: enantiomers of the parent compound and the active
metabolite differ by their metabolism and pharmacology.
The extended release (ER) form is preferentially used.
The active metabolite O-desmethylvenlafaxine undergoes renal
elimination.
References • Arzneimittelkompendium Schweiz. Basel: Documed, 2006.
• Holliday SM, Benfield P. Venlafaxine. A review of its pharmacology
and therapeutic potential in depression. Drugs 1995;49:280–94.
• Eap CB, Lessard, E, Baumann P, Brawand-Amey M, Yessine MA,
O’Hara G, Turgeon J. Role of CYP2D6 in the stereoselective
disposition of venlafaxine in humans. Pharmacogenetics 2003;13:39–47.
• Baumann PB, Hiemke C, Ulrich S, Eckermann G, Gaertner I, Gerlach
M, et al. The AGNP-TDM expert group consensus guidelines:
therapeutic drug monitoring in psychiatry. Pharmacopsychiatry
2004;37:246–65.
References
1. Rentsch K, Fathi M, Grignaschi N, Magnin JL, Printzen G,
Thormann W, et al. Monographs on drugs, which are fre-
quently analysed in the course of therapeutic drug monitor-
ing. J Lab Med 2005;29:287–97.
2. Rentsch K, Baumann P, Fathi M, Grignaschi N, Magnin JL,
Thormann W, et al. Drug monographs on drugs, which are
frequently analysed in the context of therapeutic drug moni-
toring. J Lab Med 2006;30:443–52.
3. Rentsch K, Eap CB, Fathi M, Grignaschi N, Magnin JL, Thor-
mann W, et al. Monograph on drugs which are frequently ana-
lyzed in therapeutic drug monitoring. J Lab Med 2008;32:
372–81.
